Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & metabolism Pub Date : 2023-09-01 DOI:10.1016/j.diabet.2023.101466

Valeria Grancini , Andrea Gramegna , Laura Zazzeron , Gianfranco Alicandro , Laura L Porcaro , Federica Piedepalumbo , Chiara Lanfranchi , Valeria Daccò , Emanuela Orsi , Francesco Blasi

{"title":"Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","authors":"Valeria Grancini , Andrea Gramegna , Laura Zazzeron , Gianfranco Alicandro , Laura L Porcaro , Federica Piedepalumbo , Chiara Lanfranchi , Valeria Daccò , Emanuela Orsi , Francesco Blasi","doi":"10.1016/j.diabet.2023.101466","DOIUrl":null,"url":null,"abstract":"<div>Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results.We conducted a prospective observational study on 24 CF patients with CF-related diabetes requiring insulin therapy, with the aim to evaluate the effectiveness of ETI on glucose metabolism, glucose variability and body composition. After six months of treatment, HbA1c and coefficient of variation, measured through flash or continuous glucose monitoring, significantly decreased (median changes: -0.5, P = 0.029 and -6.3, P = 0.008, respectively), despite unchanged insulin requirements.Over the treatment period, percent of fat mass increased by a median value of 3% (p = 0.029).</div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363623000484","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are a group of new drugs for the treatment of cystic fibrosis (CF) and elexacaftor + tezacaftor + ivacaftor (ETI) triple combination therapy has been approved as first choice therapy in the treatment of patients with at least 1 copy of F508del variation. Data on the effects of CFTR modulators on glucose metabolism are limited to small studies with conflicting results.

We conducted a prospective observational study on 24 CF patients with CF-related diabetes requiring insulin therapy, with the aim to evaluate the effectiveness of ETI on glucose metabolism, glucose variability and body composition. After six months of treatment, HbA1c and coefficient of variation, measured through flash or continuous glucose monitoring, significantly decreased (median changes: -0.5, P = 0.029 and -6.3, P = 0.008, respectively), despite unchanged insulin requirements.

Over the treatment period, percent of fat mass increased by a median value of 3% (p = 0.029).

查看原文本刊更多论文

依乐卡福/替扎卡福/依伐卡福三联疗法对囊性纤维化相关糖尿病患者血糖控制和身体成分的影响。

囊性纤维化跨膜电导调节因子（CFTR）调节剂是一组治疗囊性纤维化（CF）的新药，依沙卡福+替扎卡福+依伐卡福（ETI）三联疗法已被批准为治疗至少1个F508del变异患者的首选疗法。关于CFTR调节剂对葡萄糖代谢影响的数据仅限于小型研究，结果相互矛盾。我们对24名需要胰岛素治疗的CF相关糖尿病CF患者进行了一项前瞻性观察性研究，目的是评估ETI对葡萄糖代谢、葡萄糖变异性和身体成分的有效性。治疗6个月后，通过快速或连续血糖监测测量的HbA1c和变异系数显著降低（中位变化：分别为-0.5，P=0.029和-6.3，P=0.008），尽管胰岛素需求没有变化。在治疗期间，脂肪质量百分比增加了3%的中值（p=0.029）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & metabolism 医学-内分泌学与代谢

CiteScore

12.00

自引率

4.20%

发文量

审稿时长

13 days

期刊介绍： A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.

文献相关原料

公司名称	产品信息	采购帮参考价格